| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1109784785 |
| P356 | DOI | 10.1186/S13287-018-1055-2 |
| P932 | PMC publication ID | 6225696 |
| P698 | PubMed publication ID | 30409192 |
| P50 | author | Bartha Knoppers | Q2885924 |
| Erika Kleiderman | Q88147526 | ||
| P2093 | author name string | Craig Hasilo | |
| Audrey Boily | |||
| P2860 | cites work | Current practices and reform proposals for the regulation of advanced medicinal products in Canada | Q26799720 |
| Why regenerative stem cell medicine progresses slower than expected | Q28245006 | ||
| RESEARCH ETHICS. Ethics review for international data-intensive research | Q28604024 | ||
| Commercialization and stem cell research: a review of emerging issues | Q28660837 | ||
| A guide to organizing a multicenter clinical trial | Q30387845 | ||
| Bioethics of Clinical Applications of Stem Cells. | Q33624703 | ||
| Ethical issues in stem cell research and therapy | Q33900583 | ||
| Clarifying Stem-Cell Therapy's Benefits and Risks | Q34547244 | ||
| Bone marrow transplantation in Canada | Q35228489 | ||
| Challenges in the translation and commercialization of cell therapies | Q35739401 | ||
| Hurdles to clinical translation of human induced pluripotent stem cells | Q36040255 | ||
| US Food and Drug Administration international collaborations for cellular therapy product regulation | Q36632895 | ||
| Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines | Q37017086 | ||
| Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model. | Q37052853 | ||
| European regulatory tools for advanced therapy medicinal products | Q37513945 | ||
| Stem cells and ethics: current issues | Q37600705 | ||
| Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations. | Q38372717 | ||
| Comparing national home-keeping and the regulation of translational stem cell applications: An international perspective. | Q38381941 | ||
| Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving? | Q38683154 | ||
| Social Responsibility in Stem Cell Research - Is the News All Bad? | Q38713236 | ||
| Stem cell therapy clinical research: A regulatory conundrum for academia | Q38985487 | ||
| The translation of cell-based therapies: clinical landscape and manufacturing challenges. | Q39063831 | ||
| The global cell therapy industry continues to rise during the second and third quarters of 2012. | Q39507519 | ||
| The evolution of policy issues in stem cell research: an international survey | Q39576444 | ||
| Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts | Q41600980 | ||
| Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells | Q45001494 | ||
| Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry | Q46070761 | ||
| Stem cell therapies in clinical trials: workshop on best practices and the need for harmonization | Q46917700 | ||
| Can harmonized regulation overcome intra-European differences? Insights from a European Phase III stem cell trial | Q47190431 | ||
| Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations. | Q47275458 | ||
| Gene therapy comes of age. | Q47554885 | ||
| Global Distribution of Businesses Marketing Stem Cell-Based Interventions | Q47610375 | ||
| Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada | Q47614686 | ||
| Rejuvenating Regenerative Medicine Regulation. | Q50103315 | ||
| A blueprint for the next generation of ELSI research, training, and outreach in regenerative medicine. | Q50848134 | ||
| Balancing Safety and Innovation for Cell-Based Regenerative Medicine. | Q52669248 | ||
| Deciphering the EU clinical trials regulation. | Q52855112 | ||
| The Next Phase of Human Gene-Therapy Oversight | Q57281385 | ||
| How mutually recognizable is mutual recognition? An international terminology index of research ethics review policies in the USA, Canada, UK and Australia | Q58660013 | ||
| Regulation of stem cell-based therapies in Canada: current issues and concerns | Q83629959 | ||
| Bridging stem cell research and medicine: a learning health system | Q90460448 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | regenerative medicine | Q1061415 |
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | 307 | |
| P577 | publication date | 2018-11-08 | |
| P1433 | published in | Stem Cell Research & Therapy | Q14390536 |
| P1476 | title | Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials | |
| P478 | volume | 9 |
| Q92908774 | Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521 | cites work | P2860 |
Search more.